Early diagnosis and treatment of Alzheimer’s disease

References

• Ferri C, Prince M, Brayne C et al. Global prevalence of dementia: a Delphi consensus study. Lancet366(9503), 2112–2117 (2005).
   PubMed Web of Science ®Google Scholar
• Olafsdottir M, Skoog I, Marcusson J. Detection of dementia in primary care: the Linkoping study. Dement. Geriatr. Cogn. Disord.11, 223–229 (2000).
   PubMed Web of Science ®Google Scholar
• Solomon P, Brush M, Calvo V et al. Identifying dementia in the primary care practice. Int. Psychogeriatr.12(4), 483–493 (2000).
   PubMed Web of Science ®Google Scholar
• Valcour V, Masaki K, Curb J, Blanchette P. The detection of dementia in the primary care setting. Arch. Intern. Med.160, 2964–2968 (2000).
   PubMed Web of Science ®Google Scholar
• Ross G, Abbott R, Petrovitch H et al. Frequency and characteristics of silent dementia among elderly Japanese–American men. The Honolulu–Asia Aging Study. JAMA277(10), 800–805 (1997).
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer’s disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol.60(8), 1119–1122 (2003).
   PubMed Web of Science ®Google Scholar
• Solomon P, Murphy C. Should we screen for Alzheimer’s disease? A review of the evidence for and against screening for Alzheimer’s disease in primary care practice. Geriatrics60(11), 26–31 (2005).
   PubMed Web of Science ®Google Scholar
• Resnick N. Geriatric medicine and the elderly patient. In: Current Medical Diagnosis and Treatment (33rd Edition). Tierney L, McPhee S, Papadakis M (Eds). Appleton and Lange, CT, USA, 557–558 (1994).
   Google Scholar
• Stoppe G, Sandholzer H, Staedt J et al. Diagnosis of dementia in primary care: results of a representative survey in Lower Saxony, Germany. Eur. Arch. Psychiatry Clin. Neurosci.244(5), 278–283 (1994).
   PubMedGoogle Scholar
• Gifford D, Cummings J. Evaluating dementia screening tests: methodological standards to rate their performance. Neurology52(2), 224–227 (1999).
   PubMed Web of Science ®Google Scholar
• Cooper P, Tallman K, Tuokko H, Beattie B. Vehicle crash involvement and cognitive decline in older adults. J. Safety Research24, 9–17 (1993).
   Web of Science ®Google Scholar
• Larson E, Reifler B, Featherstone H, English D. Dementia in elderly outpatients: a prospective study. Ann. Intern. Med.100(3), 417–423 (1984).
   PubMed Web of Science ®Google Scholar
• Tractenberg R, Aisen P, Chuang Y. One-trial 10-item free-recall performance in Taiwanese elderly and near elderly: a potential screen for cognitive decline. Am. J. Alzheimer’s Dis. Other Demen.20, 239–247 (2005).
   PubMedGoogle Scholar
• Fillet H, Hill J, Futterman R. Health care utilization and costs of Alzheimer’s disease: the role of co-morbid conditions, disease stage and pharmacotherapy. Fam. Med.20, 528–535 (2002).
   Google Scholar
• Relkin N. Screening and early diagnosis of dementia. Am. J. Manag. Care65(Suppl.), S1111–S1124 (2000).
   Google Scholar
• Boustani M, Peterson B, Hanson L, Harris R, Lohr K. U.S. Preventive Service Task Force. Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Service Task Force. Ann. Intern. Med.138(11), 927–937 (2003).
   PubMed Web of Science ®Google Scholar
• Ashford JW, Borson S, O’Hara R et al. Should older adults be screened for dementia? Alzheimer’s Dement.2, 76–85 (2006).
   PubMedGoogle Scholar
• Brayne C, Fox C, Boustani M. Dementia screening in primary care: is it time? JAMA298(20), 2409–2411 (2007).
   PubMed Web of Science ®Google Scholar
• Solomon P, Murphy C. Comment on: Brayne C, Fox C, Boustani M. Dementia screening in primary care: is it time? JAMA298(20), 2409–2411 (2007). Alzheimer Research Forum, 3 January, 2008.
   PubMedGoogle Scholar
• Rabins PV, Cummings JL, Relkin NR. The Masters Program in Early Detection of Alzheimer’s Disease. Johns Hopkins School of Medicine Continuing Medical Education, MD, USA (2007).
   Google Scholar
• Fillet H, Doody R, Binaso K et al. Recommendations for best practices in the treatment of Alzheimer’s disease in managed care. Am. J. Ger. Pharma.4(Suppl. A), S9–S24 (2006).
   Google Scholar
• Alzheimer’s Disease Screening Discussion Group, Washington, DC, USA, November 2007.
   Google Scholar
• Braak H, Braak E. Frequency of stages of Alzheimer related lesions in different age categories. Neurobiol. Aging18, 351–357 (1997).
   PubMed Web of Science ®Google Scholar
• Selkoe D. Alzheimer’s disesase: genes, proteins and therapy. Physiol. Rev.81, 741–766 (2001).
   PubMed Web of Science ®Google Scholar
• Klafki H, Staufenbiel M, Kornhuber J et al. Therapeutic approaches to Alzheimer’s disease. Brain129, 2840–2855 (2006).
   PubMed Web of Science ®Google Scholar
• Klunk W, Engler H, Nordberg A et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburg Compound-B. Ann. Neurol.55, 306–319 (2004).
   PubMed Web of Science ®Google Scholar
• Mintun M, Larossa G, Sheline Y et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer’s disease. Neurology55, 446–452 (2006).
   Google Scholar
• Rowe C, Ng S, Mulligan R et al. First results from human studies of a novel F-18 PET ligand for brain ßâ?“amyloid imaging. J. Nucl. Med. Meeting Abstracts48, 57 (2007).
   Google Scholar
• McKahann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work goup under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34(7), 939–944 (1984).
   PubMedGoogle Scholar
• DuBois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol.7, 734–746 (2007).
   Google Scholar
• Birks J. Cholinsterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev.25(1), CD005593 (2006).
   Google Scholar
• Winblad B, Kilander L, Eriksson S et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet(367), 1057–1065 (2006).
   PubMedGoogle Scholar
• Hogan D, Goldlist B, Nagalie G, Patterson C. Comparison studies of cholinesterase inhibitors for Alzheimer’s disease. Lancet Neurol.(3), 622–626 (2004).
   PubMedGoogle Scholar
• Peskind R, Potkin S, Pomara N et al. Memantine treatment in mild to moderate Alzheimer’s disease: a 24-week randomized, controlled trial. Am. Ger. Psychiatry(14), 704–715[A] (2006).
   Google Scholar
• Kawashima R, Okita K, Yamazaki R et al. Reading aloud and arithmetic calculation improve frontal function of people with dementia. J. Gerontology60A(3), 380–384 (2005).
   Google Scholar
• Mahncke HW, Conner BB, Appelman J et al. Memory enhancement in healthy older adults using a brain plasticity-based training program: a randomized, controlled study. Proc. Natl Acad. Sci. USA103(33), 12523–12528 (2006).
   PubMed Web of Science ®Google Scholar
• Solomon P. The psychopharmacology of herbal extracts: issues and challenges. Psychopharmacology (Berl.)179(3), 710–711 (2004).
   Google Scholar
• Willis S, Tennestedt S, Marsiske M et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA(296), 2805–2814 (2006).
   PubMedGoogle Scholar
• Solomon P, Budson A. Clinical symposia: Alzheimer’s disease. Dannemiller Memorial Educational Foundation (formerly Ciba Symposium).54(1), 1–44 (2003).
   Google Scholar
• Lemere CA, Maron R, Spooner ET et al. Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. NY Acad. Sci.920, 328–331 (2000).
   PubMed Web of Science ®Google Scholar
• Gilman S, Koller M, Black RS et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology64(9), 1553–1562 (2005).
   PubMed Web of Science ®Google Scholar
• Hock C, Konietzko U, Streffer JR et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer’s disease. Neuron38(4), 547–554 (2003).
   PubMed Web of Science ®Google Scholar
• Siemers E, Skinner M, Dean RA et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin. Neuropharmacol.28(3) 126–132 (2005).
   PubMed Web of Science ®Google Scholar
• Selkoe D, Kopan R. Notch and presenilin: regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci.26, 565–597 (2003).
   PubMed Web of Science ®Google Scholar
• Golde TE. Amyloid and amyloid-like protein aggregates in neurodegenerative disease. In: The Blue Books of Neurology (The Dementias 2). Schapira AHV, Samuels MA (Series Eds). Growdon JH, Rossor MN (Vol. Eds). Butterworth Heinemann Elsevier Publishers, PA, USA, 1–32 (2007).
   Google Scholar
• Golde TE. Alzheimer’s disease therapy: can the amyloid cascade be halted? J. Clin. Invest.111, 11–18 (2003).
   PubMed Web of Science ®Google Scholar
• Aisen PS, Saumier D, Briand R et al. A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer’s disease. Neurology67(10), 1757–1763 (2006).
   PubMed Web of Science ®Google Scholar
• Wolozin B, Kellman W, Rousseau P et al. Decreased prevelance of Alzheimer’s disease with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol.57, 1439–1443 (2000).
   PubMed Web of Science ®Google Scholar
• Etminin M, Gill S, Samii A. Effect of non-steriodal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. Br. Med. J.327, 128–132 (2003).
   PubMedGoogle Scholar
• Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer’s disease progression: a randomized, controlled trial. JAMA(289), 2819–2826 (2003).
   PubMedGoogle Scholar
• Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, α-tocopherol, or both as treatment of Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N. Engl. J. Med.336(17), 1216–1222 (1997).
   PubMed Web of Science ®Google Scholar
• Petersen RC, Ronald TG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med.352(23), 2379–2388 (2006).
   Google Scholar
• Miller ER, Pastor-Barriuso R, Dalal D et al. Meta-analysis: high-dosage vitamin E supplementation may increase all cause mortality. Ann. Intern. Med.142(1), 1–10 (2005).
   PubMedGoogle Scholar
• Le Bars PL, Katz MM, Berman N et al. A placebo-controlled, double-blind, randomized trial of an extract of gingko biloba for dementia. JAMA278(16), 1327–1332 (1997).
   PubMed Web of Science ®Google Scholar
• Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R. Gingko for memory enhancement: a randomized controlled trial. JAMA288(7) 835–840 (2002).
   PubMed Web of Science ®Google Scholar
• Schaefer E, Bongard V, Beiser A et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer’s disease. Arch. Neurol.63, 1545–1550 (2006).
   PubMed Web of Science ®Google Scholar
• Fox NC, Black RS, Gilman S et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer’s disease. Neurology64(9), 1563–1572 (2005).
   PubMed Web of Science ®Google Scholar
• Knapp MJ, Knopman DS, Solomon PR et al. A 30-week randomized, controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA271(13), 985–991 (1994).
   PubMed Web of Science ®Google Scholar
• Murphy C, Solomon T, Im A, Stashwick C, Solomon P. Is Alzheimer’s disease being diagnosed earlier: a 10-year retrospective study. International Psychogeriatrics15(Suppl. 2), 89 (2003).
   PubMedGoogle Scholar